## Forty to 50% of depressed patients who are initially prescribed antidepressant medications or administered electroconvulsive therapy do not experience a timely remission. This group typifies treatment-refractory depression (TRD), defined as a failure to demonstrate an "adequate" response to an "a
Testing atypical depression definitions
β Scribed by Franco Benazzi
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 164 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1049-8931
- DOI
- 10.1002/mpr.19
No coin nor oath required. For personal study only.
β¦ Synopsis
The evidence supporting the DSM-IV definition of atypical depression (AD) is weak. This study aimed to test different definitions of AD. Major depressive disorder (MDD) patients (N = 254) and bipolar-II (BP-II) outpatients (N = 348) were interviewed consecutively, during major depressive episodes, with the Structured Clinical Interview for DSM-IV. DSM-IV criteria for AD were followed. AD validators were female gender, young onset, BP-II, axis I comorbidity, bipolar family history. Frequency of DSM-IV AD was 43.0%. AD, versus non-AD, was significantly associated with all AD validators, apart from comorbidity when controlling for age and sex. Factor analysis of atypical symptoms found factor 1 including oversleeping, overeating and weight gain (leaden paralysis at trend correlation), and factor 2 including interpersonal sensitivity, mood reactivity, and leaden paralysis. Multiple logistic regression of factor 1 versus AD validators found significant associations with several validators (including bipolar family history), whereas factor 2 had no significant associations.
Findings may support a new definition of AD based on the state-dependent features oversleeping and overeating (plus perhaps leaden paralysis) versus the current AD definition based on a combination of state and trait features. Pharmacological studies are required to support any new definition of AD, as the current concept of AD is based on different response to TCA antidepressants versus non-AD.
π SIMILAR VOLUMES
Sixteen patients meeting our criteria for atypical depression were treated in a 7-week single-blind pilot study with cilobamine mesylate, an investigational antidepressant structurally distinct from tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI). Nine patients (56 per cent)
The study was designed to test the efficacy of desipramine in adolescents with major depression (MDD). In addition, we assessed the presence of atypical features of MDD, consisting of mood reactivity and two of four associated features (rejection sensitivity, hyperphagia, hypersomnia, and leaden par
## Abstract This is a discussion of the following two papers appearing in this special issue on adaptive designs: βAn adaptive hierarchical test procedure for selecting safe and efficient treatmentsβ by Franz KΓΆnig, Peter Bauer and Werner Brannath, and βAn adaptive twoβstage design with treatment s